

(51) International Patent Classification:
G01N 33/558 (2006.01) *G01N 33/68* (2006.01)(21) International Application Number:
PCT/US2011/056777(22) International Filing Date:
18 October 2011 (18.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/394,269 18 October 2010 (18.10.2010) US(71) Applicant (for all designated States except US):
PROMETHEUS LABORATORIES INC. [US/US];
9410 Carroll Park Drive, San Diego, CA 92121-5201
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Shui Long**
[US/US]; 4555 Saddle Mountain Court, San Diego, Cali-
fornia 92130 (US). **OHRMUND, Linda** [US/US]; 3519
Tennyson Street, San Diego, California 92106 (US).
HAUENSTEIN, Scott [US/US]; 3565 Caminito El Rin-
con #211, San Diego, California 92130 (US). **SINGH,**
Sharat [US/US]; 8171 Top of the Morning Way, Rancho
Santa Fe, California 92127 (US).(74) Agents: **HAO, Joe C.** et al.; Kilpatrick Townsend &
Stockton LLP, Two Embarcadero Center, Eighth Floor,
San Francisco, California 94111-3834 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT,
LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS FOR DETERMINING ANTI-DRUG ANTIBODY ISOTYPES




FIG. 23

(57) Abstract: The present invention provides assay methods for the determination of one or more anti-drug antibody (ADA) iso-
types in a sample. As a non-limiting example, the assays of the present invention are particularly useful for determining different
ADA isotypes in samples from ADA-positive patients receiving an anti-TNF α drug such as REMICADE™ (infliximab) or HUMI-
RA™ (adalimumab). The present invention also provides methods for optimizing therapy and/or reducing toxicity in subjects re-
ceiving TNF α inhibitors for the treatment of TNF α -mediated disease or disorders.